COMT inhibition in Parkinson’s Disease
Disease progression
PD progression is characterised by a worsening of motor and non-motor features, which can no longer be managed with symptomatic therapies1. Levodopa-induced motor complications are common due to increased disease severity and higher drug doses which cause a narrowing of the levodopa therapeutic window2.
As PD advances complications related to long-term symptomatic treatment emerge, these include non-motor and motor fluctuations (Figure 1) as well as dyskinesia and psychosis1:
Developed by EPG Health for Medthority in collaboration with BIAL, with content provided by BIAL. Job code: ON/FEV20/G/183.